Literature DB >> 23108361

Nicotine vaccines to treat tobacco dependence.

Maciej L Goniewicz1, Marcin Delijewski.   

Abstract

Tobacco smoking is globally far more widespread than use of any other substance of abuse. Nicotine is an important tobacco constituent that is responsible for addictive properties of smoking. The currently available medications for the treatment of nicotine addiction have limited efficacy. A challenging novel therapeutic concept is vaccination against nicotine. An efficient vaccine would generate antibodies that sequester nicotine in the blood and prevent its access to the brain. The vaccine would have great potential for treating nicotine addiction and for relapse prevention. We reviewed the current status of vaccines against nicotine addiction that are undergoing clinical trials or are in preclinical development. We discuss problems associated with the development of nicotine vaccines, their efficacy in addiction treatment, challenges and ethical concerns. Existing evidence indicates that nicotine vaccination is well tolerated and capable of inducing an immune response but its effectiveness in increasing smoking abstinence has not been shown so far.

Entities:  

Keywords:  cigarette smoking; dopamine; drugs of abuse; nicotine; nicotine addiction; relapse prevention; smoking cessation; vaccines

Mesh:

Substances:

Year:  2012        PMID: 23108361      PMCID: PMC3667928          DOI: 10.4161/hv.22060

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  58 in total

1.  A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats.

Authors:  Qian-Qian Li; Yi-Xiao Luo; Cheng-Yu Sun; Yan-Xue Xue; Wei-Li Zhu; Hai-Shui Shi; Hai-Feng Zhai; Jie Shi; Lin Lu
Journal:  J Neurochem       Date:  2011-10-28       Impact factor: 5.372

Review 2.  Is socioeconomic status in early life associated with drug use? A systematic review of the evidence.

Authors:  James Z Daniel; Matthew Hickman; John Macleod; Nicola Wiles; Anne Lingford-Hughes; Michael Farrell; Ricardo Araya; Petros Skapinakis; Jon Haynes; Glyn Lewis
Journal:  Drug Alcohol Rev       Date:  2009-03

3.  Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities.

Authors:  M Pravetoni; D E Keyler; R R Pidaparthi; F I Carroll; S P Runyon; M P Murtaugh; C A Earley; P R Pentel
Journal:  Biochem Pharmacol       Date:  2011-11-15       Impact factor: 5.858

Review 4.  Treatment of nicotine addiction: present therapeutic options and pipeline developments.

Authors:  Riccardo Polosa; Neal L Benowitz
Journal:  Trends Pharmacol Sci       Date:  2011-01-20       Impact factor: 14.819

5.  A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity.

Authors:  Patrik Maurer; Gary T Jennings; Jörg Willers; Franziska Rohner; Ylva Lindman; Kirsten Roubicek; Wolfgang A Renner; Philipp Müller; Martin F Bachmann
Journal:  Eur J Immunol       Date:  2005-07       Impact factor: 5.532

Review 6.  Nicotine addiction.

Authors:  Neal L Benowitz
Journal:  N Engl J Med       Date:  2010-06-17       Impact factor: 91.245

Review 7.  Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence.

Authors:  Amira Y Moreno; Kim D Janda
Journal:  Pharmacol Biochem Behav       Date:  2009-04       Impact factor: 3.533

Review 8.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

Review 9.  Therapeutic vaccines for substance dependence.

Authors:  Margaret Haney; Thomas R Kosten
Journal:  Expert Rev Vaccines       Date:  2004-02       Impact factor: 5.217

10.  Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure.

Authors:  Sabina H L de Villiers; Nina Lindblom; Genadiy Kalayanov; Sandra Gordon; Ivan Baraznenok; Anna Malmerfelt; Monica M Marcus; Anette M Johansson; Torgny H Svensson
Journal:  Vaccine       Date:  2010-01-07       Impact factor: 3.641

View more
  11 in total

1.  An enzymatic advance in nicotine cessation therapy.

Authors:  Song Xue; Marsida Kallupi; Bin Zhou; Lauren C Smith; Pedro O Miranda; Olivier George; Kim D Janda
Journal:  Chem Commun (Camb)       Date:  2018-02-13       Impact factor: 6.222

2.  Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: A focus on hapten localization.

Authors:  Zongmin Zhao; Yun Hu; Theresa Harmon; Paul Pentel; Marion Ehrich; Chenming Zhang
Journal:  Biomaterials       Date:  2017-05-19       Impact factor: 12.479

3.  COVID-19 Vaccine Hesitancy among Behavioral Risk Takers.

Authors:  Monideepa B Becerra; Benjamin J Becerra
Journal:  Vaccines (Basel)       Date:  2022-05-12

Review 4.  Neuroimmune basis of methamphetamine toxicity.

Authors:  Jennifer M Loftis; Aaron Janowsky
Journal:  Int Rev Neurobiol       Date:  2014       Impact factor: 3.230

Review 5.  Substance use disorders: psychoneuroimmunological mechanisms and new targets for therapy.

Authors:  Jennifer M Loftis; Marilyn Huckans
Journal:  Pharmacol Ther       Date:  2013-04-28       Impact factor: 12.310

6.  Hybrid nanoparticle-based nicotine nanovaccines: Boosting the immunological efficacy by conjugation of potent carrier proteins.

Authors:  Zongmin Zhao; Yun Hu; Theresa Harmon; Paul R Pentel; Marion Ehrich; Chenming Zhang
Journal:  Nanomedicine       Date:  2018-04-30       Impact factor: 5.307

7.  Mutual assistance of nucleus accumbens cannabinoid receptor-1 and orexin receptor-2 in response to nicotine: a single-unit study.

Authors:  Reza Fartootzadeh; Hojjatallah Alaei; Parham Reisi
Journal:  Res Pharm Sci       Date:  2021-03-05

8.  Evaluating the immunogenicity of an intranasal vaccine against nicotine in mice using the Adjuvant Finlay Proteoliposome (AFPL1).

Authors:  Nya L Fraleigh; Justin Boudreau; Nitin Bhardwaj; Nelson F Eng; Yanal Murad; Robert Lafrenie; Reinaldo Acevedo; Reynaldo Oliva; Francisco Diaz-Mitoma; Hoang-Thanh Le
Journal:  Heliyon       Date:  2016-08-26

9.  Dose-Response Effect of Antibodies to S100 Protein and Cannabinoid Receptor Type 1 in Released-Active Form in the Light-Dark Test in Mice.

Authors:  Elena V Kardash; Irina A Ertuzun; Gul'nara R Khakimova; Andrey N Kolyadin; Sergey A Tarasov; Stéphanie Wagner; Emile Andriambeloson; Vladimir T Ivashkin; Oleg I Epstein
Journal:  Dose Response       Date:  2018-06-26       Impact factor: 2.658

10.  Novel Vaccine That Blunts Fentanyl Effects and Sequesters Ultrapotent Fentanyl Analogues.

Authors:  Rodell C Barrientos; Eric W Bow; Connor Whalen; Oscar B Torres; Agnieszka Sulima; Zoltan Beck; Arthur E Jacobson; Kenner C Rice; Gary R Matyas
Journal:  Mol Pharm       Date:  2020-08-13       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.